puberty

(redirected from Central precocious puberty)
Also found in: Dictionary, Medical, Legal, Acronyms, Encyclopedia.
Related to Central precocious puberty: endometriosis
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for puberty

adolescence

Synonyms

Synonyms for puberty

the time of life between childhood and maturity

Synonyms for puberty

the time of life when sex glands become functional

References in periodicals archive ?
A GPR54-activating mutation in a patient with central precocious puberty," The New England Journal of Medicine, vol.
Regardless of etiology, central precocious puberty requires treatment.
SUPPRELIN-LA: In June 2006, Valera submitted a New Drug Application to the FDA for marketing approval of SUPPRELIN-LA, a 12-month implant for treating central precocious puberty (CPP).
Switzerland-based Debiopharm Group has completed the recruitment of central precocious puberty (CPP) patients for its Phase III clinical study with triptorelin 22.
The company added that the one-month formulation is the first product in its class to include long-term data in its label for the treatment of central precocious puberty (CPP).
Health care company Abbott (NYSE:ABT) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for two new strengths for three-month administration of Lupron Depot-PED for the treatment of children with central precocious puberty (CPP).
announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for SUPPRELIN(R)-LA, a 12-month implant for central precocious puberty (CPP), or the early onset of puberty in children.
Broad-based health care company Abbott (NYSE:ABT) announced on Tuesday that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).
17 August 2011 - US drugs and medical devices maker Abbott (NYSE:ABT) said yesterday that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).
Valera successfully completed the active clinical portion of a Phase III study for SUPPRELIN(R) -LA, a 12-month implant for the treatment of central precocious puberty, and a New Drug Application for the product candidate is expected to be submitted to the FDA in the second quarter of 2006.
announced today the successful completion of the active clinical portion of its Phase III study of Supprelin(R) LA, a 12-month implant for treating central precocious puberty (CPP), or the early onset of puberty.
Valera Pharmaceuticals today announced that it has initiated patient enrollment for a pivotal Phase III trial of a one-year implant for the hormonal treatment of central precocious puberty (CPP), an affliction characterized by the early onset of sexual development in preadolescents.
Our six-month Hydron based octreotide implant for acromegaly recently entered Phase II trials and a twelve-month histrelin implant for central precocious puberty is advancing closer to Phase III.
Full browser ?